Multicenter comparison of the diagnostic performance of free prostate- specific antigen

Robert P. Thiel, Joseph E. Oesterling, Kirk J. Wojno, Alan Wayne Partin, Daniel Wan-Yui Chan, H Ballentine Carter, Thomas A. Stamey, Anthony R. Prestigiacomo, Michael K. Brawer, Jason C. Petteway, Grant Carlson, Albert A. Luderer

Research output: Contribution to journalArticle

Abstract

Objectives. This study examined the multicenter clinical performance of noncomplexed (free) prostate-specific antigen (PSA) in men presenting with total PSA values between 2.5 to 20 ng/mL. Methods. Prebiopsy serum samples were obtained from 1,081 consecutively accrued, histologically diagnosed men between the ages of 40 and 75 years with total PSA values falling between 2.5 and 20 ng/mL. Total PSA was determined by either the Tosoh AIA-1200 or Hybritech method. Free PSA values were determined using the Dianon PSA II immunoradiometric method. Free PSA was expressed as a percentage of total PSA. Immunochemistry was performed at each accrual site. Results. Among men diagnosed with prostate cancer (CAP), only 4% (21/520) had proportions of free to total PSA values >25%. Conversely, among men with benign prostatic disease, only 2% (13/561) had proportions of free to total PSA values 25% suggest absence of malignancy. The data also suggest that age and/or prostate volume influences the serum level of free PSA but does not affect the diagnostic cutoff points of 7% and 25%. Future analysis is needed to confirm that younger men with small prostates are at higher risk for CaP.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalUrology
Volume48
Issue number6 SUPPL.
DOIs
StatePublished - Dec 1996

Fingerprint

Prostate-Specific Antigen
Prostate
Prostatic Diseases
Immunochemistry
Serum
Multicenter Studies
Prostatic Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Multicenter comparison of the diagnostic performance of free prostate- specific antigen. / Thiel, Robert P.; Oesterling, Joseph E.; Wojno, Kirk J.; Partin, Alan Wayne; Chan, Daniel Wan-Yui; Carter, H Ballentine; Stamey, Thomas A.; Prestigiacomo, Anthony R.; Brawer, Michael K.; Petteway, Jason C.; Carlson, Grant; Luderer, Albert A.

In: Urology, Vol. 48, No. 6 SUPPL., 12.1996, p. 45-50.

Research output: Contribution to journalArticle

Thiel, RP, Oesterling, JE, Wojno, KJ, Partin, AW, Chan, DW-Y, Carter, HB, Stamey, TA, Prestigiacomo, AR, Brawer, MK, Petteway, JC, Carlson, G & Luderer, AA 1996, 'Multicenter comparison of the diagnostic performance of free prostate- specific antigen', Urology, vol. 48, no. 6 SUPPL., pp. 45-50. https://doi.org/10.1016/S0090-4295(96)00609-7
Thiel, Robert P. ; Oesterling, Joseph E. ; Wojno, Kirk J. ; Partin, Alan Wayne ; Chan, Daniel Wan-Yui ; Carter, H Ballentine ; Stamey, Thomas A. ; Prestigiacomo, Anthony R. ; Brawer, Michael K. ; Petteway, Jason C. ; Carlson, Grant ; Luderer, Albert A. / Multicenter comparison of the diagnostic performance of free prostate- specific antigen. In: Urology. 1996 ; Vol. 48, No. 6 SUPPL. pp. 45-50.
@article{079ab12efd8149719d0b6840d00b73c1,
title = "Multicenter comparison of the diagnostic performance of free prostate- specific antigen",
abstract = "Objectives. This study examined the multicenter clinical performance of noncomplexed (free) prostate-specific antigen (PSA) in men presenting with total PSA values between 2.5 to 20 ng/mL. Methods. Prebiopsy serum samples were obtained from 1,081 consecutively accrued, histologically diagnosed men between the ages of 40 and 75 years with total PSA values falling between 2.5 and 20 ng/mL. Total PSA was determined by either the Tosoh AIA-1200 or Hybritech method. Free PSA values were determined using the Dianon PSA II immunoradiometric method. Free PSA was expressed as a percentage of total PSA. Immunochemistry was performed at each accrual site. Results. Among men diagnosed with prostate cancer (CAP), only 4{\%} (21/520) had proportions of free to total PSA values >25{\%}. Conversely, among men with benign prostatic disease, only 2{\%} (13/561) had proportions of free to total PSA values 25{\%} suggest absence of malignancy. The data also suggest that age and/or prostate volume influences the serum level of free PSA but does not affect the diagnostic cutoff points of 7{\%} and 25{\%}. Future analysis is needed to confirm that younger men with small prostates are at higher risk for CaP.",
author = "Thiel, {Robert P.} and Oesterling, {Joseph E.} and Wojno, {Kirk J.} and Partin, {Alan Wayne} and Chan, {Daniel Wan-Yui} and Carter, {H Ballentine} and Stamey, {Thomas A.} and Prestigiacomo, {Anthony R.} and Brawer, {Michael K.} and Petteway, {Jason C.} and Grant Carlson and Luderer, {Albert A.}",
year = "1996",
month = "12",
doi = "10.1016/S0090-4295(96)00609-7",
language = "English (US)",
volume = "48",
pages = "45--50",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Multicenter comparison of the diagnostic performance of free prostate- specific antigen

AU - Thiel, Robert P.

AU - Oesterling, Joseph E.

AU - Wojno, Kirk J.

AU - Partin, Alan Wayne

AU - Chan, Daniel Wan-Yui

AU - Carter, H Ballentine

AU - Stamey, Thomas A.

AU - Prestigiacomo, Anthony R.

AU - Brawer, Michael K.

AU - Petteway, Jason C.

AU - Carlson, Grant

AU - Luderer, Albert A.

PY - 1996/12

Y1 - 1996/12

N2 - Objectives. This study examined the multicenter clinical performance of noncomplexed (free) prostate-specific antigen (PSA) in men presenting with total PSA values between 2.5 to 20 ng/mL. Methods. Prebiopsy serum samples were obtained from 1,081 consecutively accrued, histologically diagnosed men between the ages of 40 and 75 years with total PSA values falling between 2.5 and 20 ng/mL. Total PSA was determined by either the Tosoh AIA-1200 or Hybritech method. Free PSA values were determined using the Dianon PSA II immunoradiometric method. Free PSA was expressed as a percentage of total PSA. Immunochemistry was performed at each accrual site. Results. Among men diagnosed with prostate cancer (CAP), only 4% (21/520) had proportions of free to total PSA values >25%. Conversely, among men with benign prostatic disease, only 2% (13/561) had proportions of free to total PSA values 25% suggest absence of malignancy. The data also suggest that age and/or prostate volume influences the serum level of free PSA but does not affect the diagnostic cutoff points of 7% and 25%. Future analysis is needed to confirm that younger men with small prostates are at higher risk for CaP.

AB - Objectives. This study examined the multicenter clinical performance of noncomplexed (free) prostate-specific antigen (PSA) in men presenting with total PSA values between 2.5 to 20 ng/mL. Methods. Prebiopsy serum samples were obtained from 1,081 consecutively accrued, histologically diagnosed men between the ages of 40 and 75 years with total PSA values falling between 2.5 and 20 ng/mL. Total PSA was determined by either the Tosoh AIA-1200 or Hybritech method. Free PSA values were determined using the Dianon PSA II immunoradiometric method. Free PSA was expressed as a percentage of total PSA. Immunochemistry was performed at each accrual site. Results. Among men diagnosed with prostate cancer (CAP), only 4% (21/520) had proportions of free to total PSA values >25%. Conversely, among men with benign prostatic disease, only 2% (13/561) had proportions of free to total PSA values 25% suggest absence of malignancy. The data also suggest that age and/or prostate volume influences the serum level of free PSA but does not affect the diagnostic cutoff points of 7% and 25%. Future analysis is needed to confirm that younger men with small prostates are at higher risk for CaP.

UR - http://www.scopus.com/inward/record.url?scp=0030460436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030460436&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00609-7

DO - 10.1016/S0090-4295(96)00609-7

M3 - Article

C2 - 8973699

AN - SCOPUS:0030460436

VL - 48

SP - 45

EP - 50

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6 SUPPL.

ER -